Krazati (adagrasib) — CareFirst (Caremark)
recurrent, locally advanced, or metastatic pancreatic adenocarcinoma
Initial criteria
- Tumor or plasma specimen is positive for KRAS G12C mutation
- Member has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Requested medication will be used as a single agent
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months